References
Adrogue HJ, Frazier MR, Zeluff B, Suki WN. Systemic calciphylaxis revisited. Am J Nephrol 1981; 1: 177–83.
Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 2008; 3: 1139–43.
Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009; 19: 12–9.
Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001; 60: 324–32.
Sandhu G, Casares P, Ranade A, et al. Acute calciphylaxis precipitated by the initiation of hemodialysis. Clin Nephrol 2013; 80: 301–5.
Weenig RH. Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol 2008; 58: 458–71.
Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998; 128: 657–62.
Funabiki K, Kaneko S, Terajima M, Tomita H, Kawano Y, Tomino Y. A case of multicentric Castleman’s disease associated with renal amyloidosis and pure red cell aplasia. Am J Nephrol 1998; 18: 247. 50.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Honda, Y., Endo, Y., Tanizaki, H. et al. Calciphylaxis associated with acute renal failure in multicentric Castleman’s disease. Eur J Dermatol 25, 497–499 (2015). https://doi.org/10.1684/ejd.2015.2627
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2015.2627